CALCA and migraine disorder: Walker and colleagues showed the presence of CTR, and furthermore, they suggested that the AMY1 receptor (CTR/RAMP1) could be a relevant target for CGRP and perhaps a novel way in migraine therapy (Walker et al. 2015).